The Delhi High Court on Friday stayed the Central Government's decision to restrain private companies from manufacturing and selling oxytocin drug till October.
A bench of Justices S. Ravindra Bhat and A. K. Chawla in an interim order suspended the government's decision till October and listed the matter for further hearing on September 12.
The court was hearing pleas of Mylan Laboratories' subsidiary BGP Products Operations GmbH, Neon Laboratories and NGO All India Drug Action Network (AIDAN).
The government has restricted its manufacture to the public sector only and allowed state-run Karnataka Antibiotics and Pharmaceuticals Ltd (KAPL) to produce it for domestic use.
The decision taken under Section 26A of the Drugs and Cosmetics Act, 1940 is aimed at checking the misuse of oxytocin, a reproductive hormone found in mammals that increases the contraction of the uterus during labour and stimulates ejection of milk into the ducts of the breasts.
--IANS
akk/anp/sed
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
